New Anti Diabetic Drug with Multiple Mechanisms of Action | UPDATES IN MEDICINE
New Anti Diabetic Drug with Multiple Mechanisms of Action
● Tirzepatide versus Semaglutide for Type 2 Diabetes
This open-label, 40-week, phase 3 trial assessed the efficacy and safety of tirzepatide, a weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist under development for type 2 diabetes. Tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks.
